Search Results

KRN-633 10 mg  | 99.65%

TargetMol

KRN-633 is an effective VEGFR inhibitor. The IC50s of KRN-633(KRN633) for VEGFR1, VEGFR2, and VEGFR3 is 170, 160 and 125 nM, respectively.

More Information Supplier Page

IMD-0354 5 mg  | 99.56%

TargetMol

IMD-0354 (IKK2 Inhibitor V) is an IKKβ inhibitor and inhibits IκBα phosphorylation in NF-κB pathway.

More Information Supplier Page

PD318088 10 mg  | 99.81%

TargetMol

PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binding simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.

More Information Supplier Page

PD318088 5 mg  | 99.81%

TargetMol

PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binding simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.

More Information Supplier Page

PD318088 50 mg  | 99.81%

TargetMol

PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binding simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.

More Information Supplier Page

PD318088 2 mg  | 99.81%

TargetMol

PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binding simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.

More Information Supplier Page

PD318088 25 mg  | 99.81%

TargetMol

PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binding simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.

More Information Supplier Page

CCT196969 5 mg  | 99.65%

TargetMol

CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.

More Information Supplier Page